ClearView Healthcare Partners

Thinking about applying to our Connect to ClearView program? Join one of our four virtual information sessions to learn more about the opportunity, meet the team and hear what makes C2C unique. See details below and register today. We’d love to see you there! January 29th –https://lnkd.in/esvgr73F February 4th –https://lnkd.in/eaXBP_MZ February 5th – https://lnkd.in/edwMGTVX February 11th – https://lnkd.in/enGAe3XA #ClearViewhcp #PhDhiring #lifescienceconsulting #HiringNow #JoinUs #YourFutureIsInClearView

Happy New Year! ClearView is kicking off 2026 with experienced level needs across many of our focus areas as the company continues to grow. Please check out our careers page to check them all out and apply to any of interest. https://lnkd.in/gHryjuqJ #clearviewhcp #yourfutureisinclearview #lifesciencesconsulting #experiencedhire

Ready to apply your scientific expertise in a strategic, high‑impact setting? Connect to ClearView applications are now open for the US and UK! Spend three immersive days this Spring working alongside our consultants where you'll collaborate with ClearView managers and leaders, learn our approach to problem‑solving, and experience the supportive community that defines our firm. Apply early - spots fill quickly: https://lnkd.in/gHryjuqJ #PhDhiring #lifescienceconsulting #HiringNow #ClearViewhcp #YourFutureIsInClearView

We're back with another episode of ClearView Convos! In this episode host Sam Ulin sits down with ClearView alumnus and obesity thought leader Michael Weintraub, MD to explore what’s next in obesity care. Dr. Weintraub not only practices and teaches in the endocrinology department at NYU Langone, he also serves as Co-Chair of the Obesity Pharmacotherapy Guidelines Committee for the Endocrine Society and contributes as an exam writer for the American Board of Obesity Medicine. Dr. Weintraub emphasizes that there's truly "no one-size-fits-all" approach to treating obesity, highlighting the importance of a multidisciplinary, patient-specific treatment approach. He notes that guidelines are beginning to reflect this shift, citing the recently published EASO guidance document which tailors treatment recommendations based on comorbidities and available evidence. Dr. Weintraub also shares hypotheses on where the field may head next, including the emerging role of primary care providers in obesity treatment, particularly as robust oral agents become available. A big thank you to Michael Weintraub, MD for this insightful conversation! Wach the full episode here👉: https://lnkd.in/eZKGCH3y #ObesityLandscape #ObesityPharmacotherapy #Endocrinology #ClearViewConvos #ClearViewHCP

We’re excited to share that 17 members of the ClearView HealthCare Partners team will be attending JPM next week!   We’re looking forward to reconnecting with current and former clients, as well as making new connections with those we haven’t had the chance to meet yet.   If you’re attending JPM and would like to connect with a member of our team, please reach out directly so we can coordinate a meetup. #JPMorganHealthcareConference #JPM2026 #JPMHC2026 #ClearViewHCP

Therapies reach patients faster when intelligence drives the process. For the past year, Vi and ClearView Healthcare Partners have partnered to help healthcare and biopharma organizations bring therapies to patients faster by embedding intelligence directly into the decisions that guide trial design, site strategy, and commercial execution. Our depth in market, clinical, and commercial strategy + Vi’s enterprise AI platform has created a shared model for impact: • more precise patient identification • accelerated enrollment • higher in-market ROI • real-world value for the organizations we serve As we head into J.P. Morgan next week, we’re proud to show the kind of partnership that moves this industry forward and excited to continue building with the ClearView team, including Ryan Tubman This is what it looks like when strategy and AI meet at enterprise scale. If you’re at JPM and want to learn more, we’ll be there – just reach out! #Healthcare #Biopharma #EnterpriseAI #JPM2025

Happy Holidays! As we reflect on 2025 and the evolving developments in the vaccine space, we recall our ClearView Convos episode from several months ago (episode 2b, can be found on our website under insights and perspectives).   ClearView’s Vaccines Center of Excellence now takes an updated look at evolving CDC and ACIP recommendations, clinical trial expectations, and the growing importance of state and medical society recommendations in shaping vaccine strategy. These developments have important implications for how innovators approach development, access, and commercialization of vaccines.   Explore the latest insights on our white paper here: https://lnkd.in/eWhBYsGu   #ClearViewConvos #Vaccines #HealthPolicy #LifeSciences #clearviewhcp

ClearView Healthcare Partners is proud to have supported SK Capital Partners in the successful investment in Swixx BioPharma   Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. https://lnkd.in/edYrWmKZ #clearviewhcp #lifesciencesconsulting #investors

The obesity market is rapidly rewriting the rules of pharma commercialization—and these changes are set to redefine the entire industry over the coming decades. Our partner, Sam Ulin, joined forces with Mike Mortimer of GHO Capital Partners LLP to document how ClearView is helping clients build integrated, precision commercialization models in obesity and beyond. Their piece outlines a future where these models not only boost marketing ROI but also empower patients to take ownership of their health. Read the full article in BioCentury Inc. here (open access - no paywall): https://lnkd.in/e4fCcPaS Interested in learning how to build these transformative models? Reach out to Sam or other members of our Launch and Commercialization team to discover how ClearView and precision targeting partners at Vi are shaping the future of pharma commercialization. #PharmaCommercialization #ObesityCare #PrecisionMarketing #DigitalHealth #DirectToConsumer #ClearViewHCP #PrecisionTargeting

CLEARVIEW IN THE NEWS ClearView is featured in today’s Financial Times feature on the evolving obesity therapeutics market highlighting the coming impact of oral weight-loss medicines on the obesity market.   Sam Ulin shares in the FT that “injectables have established prescription weight loss as standard practice—now orals can make it commonplace and routine.” Blockbuster oral medicines expected in the next few years will not only improve accessibility but could unlock new combination treatments for related cardiometabolic conditions, broadening clinical and commercial impact.   Read the full article for more insights on how therapeutics commercialization and competition are being rewritten in obesity care: https://lnkd.in/gXt4qdC2 (paywall required)   #Obesity #GLP1 #Pharma #MetabolicHealth #ClearViewHCP